All Companies
🇬🇧
bit.bio
PrivateCoding biology to reprogram human cells
bit.bio is a Cambridge-based synthetic biology company that uses gene editing and its proprietary opti-ox technology to precisely reprogram human stem cells into any cell type. The company provides consistent, scalable human cells for drug discovery, cell therapy, and disease modeling.
Founded2016
HQCambridge, United Kingdom
CEOMark Kotter
StatusPrivate
Total Funding$150M
Pipeline
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| ioGlutamatergic Neurons | Neurological drug discovery | Commercial | opti-ox |
| Cell therapy programs | Various | Preclinical | opti-ox + gene editing |
Key People
Mark KotterCEO & Founder